Cleared Traditional

AXIOS Stent with Electrocautery Enhanced Delivery System (K150692) - FDA 510(k) Clearance

Class II Gastroenterology & Urology device cleared through predicate-based substantial equivalence.

K150692 · Boston Scientific Corp · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2015
Decision
140d
Days
Class 2
Risk

K150692 is an FDA 510(k) clearance for the AXIOS Stent with Electrocautery Enhanced Delivery System. Classified as Pancreatic Stent, Covered, Metallic, Removable (product code PCU), Class II - Special Controls.

Submitted by Boston Scientific Corp (Mountain View, US). The FDA issued a Cleared decision on August 5, 2015 after a review of 140 days - within the typical 510(k) review window.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5015 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Boston Scientific Corp devices

Submission Details

510(k) Number K150692 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 18, 2015
Decision Date August 05, 2015
Days to Decision 140 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
10d slower than avg
Panel avg: 130d · This submission: 140d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code PCU Pancreatic Stent, Covered, Metallic, Removable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 876.5015
Definition To Facilitate Transmural Endoscopic Drainage Of Pancreatic Pseudocysts
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. Clinical trial data may be submitted as supporting evidence to strengthen the substantial equivalence argument. Most Gastroenterology & Urology devices follow this clearance model.

Clinical Evidence

ClinicalTrials.gov
NCT02146352 Completed Interventional Industry-sponsored

AXIOS Stent With Electrocautery Enhanced Delivery System

30
Patients (actual)
8
Sites
Treatment
Purpose
Open label
Masking
Condition studied Pancreatic Pseudocyst(s)
Study design Single group
Eligibility All sexes · 18 Years+
Principal investigator Steven A Edmundowicz, MD
Sponsor Xlumena, Inc. (industry)
Started 2014-06-01 → Primary completion 2015-01-01 → Completed 2015-03-01
Primary outcome
Safety/Adverse Event Outcome Measure 1
Secondary outcome
Stent Retention Outcome Measure
View full study on ClinicalTrials.gov

Regulatory Peers - PCU Pancreatic Stent, Covered, Metallic, Removable

All 10
Devices cleared under the same product code (PCU) and FDA review panel - the closest regulatory comparables to K150692.
Niti-S SPAXUS Stent
K252648 · Taewoong Medical Co., Ltd. · Mar 2026
AXIOS Stent and Electrocautery-Enhanced Delivery System
K220112 · Boston Scientific Corporation · Sep 2022
AXIOS Stent and Electrocautery Enhanced Delivery System
K203132 · Boston Scientific Corporation · Apr 2021
AXIOS Stent and Electrocautery Enhanced Delivery System
K192043 · Boston Scientific Corporation · Aug 2019
AXIOS Stent and Delivery System, AXIOS Stent and Electrocautery Enhanced Delivery System
K181905 · Boston Scientific Corporation · Mar 2019
AXIOS Stent and Electrocautery Enhanced Delivery System
K163272 · Boston Scientific Corporation · Feb 2017